Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive top ...

CIRRUS-HCM is a multi-part, open-label trial of EDG-7500 in individuals with HCM. In September 2024, the Company announced positive top-line data from Part A of the trial showing that a single ...

Edgewise Therapeutics (EWTX) announced top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive ...

As previously reported yesterday, Scotiabank downgraded Edgewise Therapeutics (EWTX) to Sector Perform from Outperform with a price target of ...

(MENAFN- PR Newswire) CIRRUS-HCM is a multi-part, open-label trial of EDG-7500 in individuals with HCM. In September 2024, the Company announced positive top-line data from Part A of the trial ...

Discover growth opportunities with Edgewise Therapeutics, Inc. in the hypertrophic cardiomyopathy market. Click for my EWTX ...

Across the study, two patients experienced “serious adverse events of atrial fibrillation (AF) requiring cardioversion,” ...

Edgewise Therapeutics stock plunges 48% in a week following safety concerns for its investigational hypertrophic cardiomyopathy treatment candidate, EDG-7500.

The Cirrus-HCM trial is an open-label, four-week study evaluating the efficacy of two dosages (50 mg and 100 mg) of EDG-7500 in patients diagnosed with either obstructive or nonobstructive HCM. The ...